Eli Lilly
Eli Lilly and Company is a global pharmaceutical leader focused on the discovery, development, manufacturing, and marketing of innovative human medicines. The company specializes in high-growth therapeutic areas including cardiometabolic health, oncology, immunology, and neuroscience. Its core value proposition centers on delivering differentiated treatments that improve patient outcomes and provide value to global healthcare payers.
Financials
Based on Q4 2025 filing
Business Segments
Cardiometabolic Health
primaryFocuses on the treatment of diabetes, obesity, and related cardiovascular and kidney diseases. This segment includes the company's significant growth drivers in the incretin class.
Mounjaro, Zepbound, Trulicity, Jardiance, Basaglar, Humalog, Humulin
Wholesalers, Pharmacy Benefit Managers, Hospitals, Retail Pharmacies
Oncology
majorDevelops and markets targeted therapies for various cancers, including breast, lung, colorectal, and gastric cancers.
Verzenio, Tyvyt, Jaypirca, Retevmo, Cyramza, Erbitux, Inluriyo
Oncology Clinics, Hospitals, Government Institutions
Immunology
majorProvides treatments for autoimmune and inflammatory conditions such as plaque psoriasis, rheumatoid arthritis, and ulcerative colitis.
Taltz, Olumiant, Omvoh, Ebglyss
Specialty Pharmacies, Hospitals, Wholesalers
Neuroscience
moderateFocuses on neurological disorders, specifically migraine prevention and treatments for Alzheimer's disease.
Emgality, Kisunla
Neurologists, Hospitals, Wholesalers
Segment Financials
Other cardiometabolic health — Revenue
View metricMounjaro — Revenue
View metricTrulicity Member — Revenue
View metricVerzenio — Revenue
View metricOther Product — Revenue
View metricTaltz — Revenue
View metricISRAEL — Number of class action petitions
View metricNeuroscience — Revenue
View metricUS — Revenue
View metricBusiness Overview
Competitive Position
A leading global innovator in the pharmaceutical industry with a dominant position in the diabetes and anti-obesity markets.
Geographies
United States, Europe, Asia, China
Customer Segments
Healthcare providers, Wholesale distributors, Government health agencies, Patients
Upstream Dependencies
Raw material suppliers, Contract research organizations, Third-party manufacturing partners, Academic research institutions
Downstream Customers
McKesson Corporation, Cencora, Inc., Cardinal Health, Inc., Pharmacy Benefit Managers, Hospitals, Retail Pharmacies
Competitors & Partners
Competitors
Novo Nordisk
NVO
Primary competitor in diabetes and obesity (incretin market)
Pfizer
PFE
Global pharmaceutical competitor across multiple therapeutic areas
Amgen
AMGN
Competitor in biologics and biosimilars
McKesson
MCK
Major distributor (also listed as a customer)
Cencora
COR
Major distributor (also listed as a customer)
Cardinal Health
CAH
Major distributor (also listed as a customer)
Partners
Boehringer Ingelheim
Collaboration partner for Jardiance and Basaglar
Incyte
INCY
Collaboration partner for Olumiant
Innovent Biologics, Inc.
Collaboration partner for Tyvyt in China
Almirall S.A.
Collaboration partner for Ebglyss in Europe
Eli Lilly FAQ
Common questions about Eli Lilly
Eli Lilly and Company is a global pharmaceutical leader focused on the discovery, development, manufacturing, and marketing of innovative human medicines. The company specializes in high-growth therapeutic areas including cardiometabolic health, oncology, immunology, and neuroscience. Its core value proposition centers on delivering differentiated treatments that improve patient outcomes and provide value to global healthcare payers.
Eli Lilly is scheduled to report earnings for Q1 2026 on April 30, 2026. Analysts estimate revenue of $17.6B.
Eli Lilly generated $65.2B in trailing twelve-month revenue with net income of $20.6B, representing a net margin of 31.7%. Gross margin stands at 83.0%, with free cash flow of $9.0B. These figures are based on the Q4 2025 filing.
Eli Lilly's key competitors include Novo Nordisk, Pfizer Inc., Amgen Inc., and others. These companies compete in similar markets and product categories.
Eli Lilly has approximately 43,000 employees.